J Am Board Fam Med by Li, Jun et al.
Decrease in Prostate Cancer Testing Following the US 
Preventive Services Task Force (USPSTF) Recommendations
Jun Li, MD, PhD, Zahava Berkowitz, MSPH, MSc, and Ingrid J. Hall, PhD, MPH
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and 
Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA
Abstract
Purpose: To assess changes of prostate-specific antigen (PSA) testing following recent US 
Preventive Services Task Force (USPSTF) prostate cancer screening recommendations using 2005 
to 2013 National Health Interview Survey data.
Methods: We calculated the percentage of PSA testing among men ≥40 years by age group and 
age-adjusted race for each survey year. Differences between years were assessed with linear 
contrasts after combining all years’ data.
Results: The overall percentage of PSA testing was highest in 2008 and decreased significantly 
in 2013. Compared with 2008, each age group had significantly lower screening percentages in 
2013, especially men ≥75 years old (−14.0% points; P < .001). Both men aged 50 to 74 and men 
aged ≥75 had significantly lower percentages in 2013 than in 2010. For white and black men, the 
PSA testing percentages were highest in 2008 and decreased significantly in 2013. Only white 
men had a significantly lower percentage in 2013 than in 2010.
Conclusions: Significant declines in PSA testing from 2008 to 2013 in men ≥75 years old may 
reflect the impact of the 2008 USPSTF recommendations. While the cause of the decreases in 
PSA testing between 2010 and 2013 among men aged 50 to 74 years old and white men is 
unknown, the decreases may suggest the early effects of the 2012 recommendations.
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Prostate-specific antigen (PSA) testing for prostate cancer screening has been widely used in 
the United States in the past 3 decades. Because harms outweighed benefits, in 2012 the US 
Preventive Services Task Force (USPSTF) expanded its 2008 recommendation against PSA 
testing among men aged ≥75 years to include men of all ages.1 Translation of the USPSTF 
recommendations into practice has had to compete with different recommendations from 
many medical organizations (http://www.guideline.gov/). Men often receive messages about 
screening that differ from the USPSTF recommendations. Recent studies have shown 
conflicting results about the impact of the 2008 USP-STF recommendations on the pattern 
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of PSA testing.2–4 We examined National Health Interview Survey (NHIS) data from 2005 
to 2013 to assess patterns of PSA testing following recent USPSTF recommendations.
Methods
The NHIS is an annual, in-person, cross-sectional survey that monitors health trends (http://
www.cdc.gov/nchs/nhis.htm). The final response rates for the adult samples in 2005, 2008, 
2010, and 2013 were 69.0%, 62.6%, 60.8%, and 61.2%, respectively. We calculated the 
percentage of PSA testing for each survey year by age group and age-adjusted race among 
men ≥40 years who had no history of prostate cancer and who had a PSA test during a 
routine examination. Differences between years were assessed with linear contrasts after 
combining data from all survey years. All analyses were performed using SUDAAN 10 
software (RTI International, Research Triangle Park, NC) to account for the complex 
sampling design. A P value <.05 was considered significant.
Results
As shown in Figure 1, the overall percentage of PSA testing was highest in 2008 (31.8%) 
and decreased significantly in 2013 (24.2%). Men ≥75 years old had the highest testing 
percentage over the entire period. Compared with 2008, a significant reduction in PSA 
testing was observed in 2013 for each age group, especially for men ≥75 years old (−14.0% 
points; P < .001). Compared with 2010, significant reductions occurred in 2013 among both 
men 50 to 74 and those ≥75 years old.
Figure 2 shows that, for white and black men, the percentages of PSA testing were highest in 
2008 (33.6% and 31.1%, respectively) and decreased significantly in 2013 (24.7% and 
23.4%, respectively). Compared with 2008, no significant reduction was observed among 
Asian and Pacific Islander men in 2013. Only white men had a significant decrease in PSA 
testing between 2010 and 2013.
Discussion
After an increase in PSA testing from 2005 to 2008, we observed a significant decrease from 
2008 to 2013. Despite the decrease, men ≥75 years old continued to have the highest testing 
percentage from 2005 to 2013. Significant declines in PSA testing from 2008 to 2013 in men 
≥75 may reflect the impact of the 2008 USPSTF recommendations. While the cause of the 
decrease in PSA testing among men aged 50 to 74 between 2010 and 2013 is unknown, the 
decrease may suggest early impacts of the 2012 recommendations. A recently published 
study, which compared use of PSA testing 6 months before and after the 2012 
recommendations, showed continuing decreases in PSA testing after the recommendation.5
White men had a significantly lower percentage of PSA testing in 2013 than in 2008 or 
2010. No significant decrease in PSA testing between 2010 and 2013 was observed among 
black men. Higher risk perception among black men may partially account for the slow 
decline in PSA testing. Reasons for stable PSA testing percentage over time among Asian 
and Pacific Islander men merit further investigation. Although some decrease in PSA testing 
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has occurred in white men and men ≥75 since 2008, considerable work remains to be done if 
the goal is to fully implement the 2008 and 2012 USPSTF recommendations in practice.
Limitations of our study include reliance or self-reported data for PSA testing and possibly 
selection bias related to response rates.
Conclusion
Our study reports a decrease in self-reported receipt of the PSA test following past USPSTF 
recommendations advising against the test. Results suggest that the recommendations may 
be impacting test use, especially among older men and white men.
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Figure 1. 
Percentage of prostate-specific antigen testing within the past year, by age and year, among 
men aged ≥40 years, based on National Health Interview Survey 2005 to 2013 data. 
Percentages are weighted to the noninstitutionalized male population.
Li et al. Page 4
J Am Board Fam Med. Author manuscript; available in PMC 2018 August 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. 
Percentage of prostate-specific antigen testing within the past year, by race and year, among 
men aged ≥40 years and older, based on National Health Interview Survey 2005 to 2013 
data. Percentages of race are age-adjusted to the 2010 US standard population and are 
weighted to the noninstitutionalized male population. American Indians and Alaska Natives 
are not presented because of the small sample sizes. API, Asian/Pacific Islander.
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